Predictive Biomarkers and Patient Outcome in Platinum-Resistant (PLD-Treated) Ovarian Cancer
Identification of predictive biomarkers for ovarian cancer (OC) treatment, particularly in the platinum-resistant/refractory setting, is highly relevant for clinical management. E-cadherin, vimentin, and osteopontin (OPN) are proteins associated with tumor microenvironment (TME) remodelling that pla...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-07-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/10/8/525 |
| _version_ | 1797561044836548608 |
|---|---|
| author | Isabel J. Dionísio de Sousa Durval S. Marques Catarina Príncipe Raquel V. Portugal Sule Canberk Hugo Prazeres José M. Lopes Etel R. P. Gimba Raquel T. Lima Paula Soares |
| author_facet | Isabel J. Dionísio de Sousa Durval S. Marques Catarina Príncipe Raquel V. Portugal Sule Canberk Hugo Prazeres José M. Lopes Etel R. P. Gimba Raquel T. Lima Paula Soares |
| author_sort | Isabel J. Dionísio de Sousa |
| collection | DOAJ |
| description | Identification of predictive biomarkers for ovarian cancer (OC) treatment, particularly in the platinum-resistant/refractory setting, is highly relevant for clinical management. E-cadherin, vimentin, and osteopontin (OPN) are proteins associated with tumor microenvironment (TME) remodelling that play key roles in cancer. This study aimed to evaluate the association between the staining patterns of these proteins with survival outcomes in a series of OC patients, namely in patients with platinum-resistant/refractory disease. Low E-cadherin expression and high vimentin expression in all patient groups (as well as for E-cadherin in the platinum-resistant arm) were significantly associated with longer overall survival (OS). Low cytoplasmic OPN expression (and cytoplasmic and membrane OPN in the platinum-resistant arm) were significantly associated with longer OS. In patients that responded to treatment (pegylated liposomal doxorubicin (PLD) or other), low cytoplasmic OPN expression was also associated with longer progression-free survival (PFS). In the other hand, high nuclear OPN-c expression in patients that respond to treatment was associated with longer OS and longer PFS. Longer PFS was also associated with high expression of both nuclear and cytoplasm OPN-c, in platinum-resistant patients and in those that responded to PLD. Our study indicates that the expression of E-cadherin, vimentin, and OPN may have prognostic implications. Nuclear OPN-c and cytoplasm OPN expression are putative predictive markers in platinum-resistant (PLD treated) ovarian cancer patients. |
| first_indexed | 2024-03-10T18:08:47Z |
| format | Article |
| id | doaj.art-1c3d5046e8d14378a48849d353391654 |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-10T18:08:47Z |
| publishDate | 2020-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-1c3d5046e8d14378a48849d3533916542023-11-20T08:16:36ZengMDPI AGDiagnostics2075-44182020-07-0110852510.3390/diagnostics10080525Predictive Biomarkers and Patient Outcome in Platinum-Resistant (PLD-Treated) Ovarian CancerIsabel J. Dionísio de Sousa0Durval S. Marques1Catarina Príncipe2Raquel V. Portugal3Sule Canberk4Hugo Prazeres5José M. Lopes6Etel R. P. Gimba7Raquel T. Lima8Paula Soares9Faculty of Medicine, University of Porto, 4200-319 Porto, PortugalNatural Science Department, Health and Humanities Institute, Fluminense Federal University, Rio das Ostras 28895-532, Brazili3S—Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, PortugalFaculty of Medicine, University of Porto, 4200-319 Porto, Portugali3S—Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugali3S—Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, PortugalFaculty of Medicine, University of Porto, 4200-319 Porto, PortugalNatural Science Department, Health and Humanities Institute, Fluminense Federal University, Rio das Ostras 28895-532, BrazilFaculty of Medicine, University of Porto, 4200-319 Porto, PortugalFaculty of Medicine, University of Porto, 4200-319 Porto, PortugalIdentification of predictive biomarkers for ovarian cancer (OC) treatment, particularly in the platinum-resistant/refractory setting, is highly relevant for clinical management. E-cadherin, vimentin, and osteopontin (OPN) are proteins associated with tumor microenvironment (TME) remodelling that play key roles in cancer. This study aimed to evaluate the association between the staining patterns of these proteins with survival outcomes in a series of OC patients, namely in patients with platinum-resistant/refractory disease. Low E-cadherin expression and high vimentin expression in all patient groups (as well as for E-cadherin in the platinum-resistant arm) were significantly associated with longer overall survival (OS). Low cytoplasmic OPN expression (and cytoplasmic and membrane OPN in the platinum-resistant arm) were significantly associated with longer OS. In patients that responded to treatment (pegylated liposomal doxorubicin (PLD) or other), low cytoplasmic OPN expression was also associated with longer progression-free survival (PFS). In the other hand, high nuclear OPN-c expression in patients that respond to treatment was associated with longer OS and longer PFS. Longer PFS was also associated with high expression of both nuclear and cytoplasm OPN-c, in platinum-resistant patients and in those that responded to PLD. Our study indicates that the expression of E-cadherin, vimentin, and OPN may have prognostic implications. Nuclear OPN-c and cytoplasm OPN expression are putative predictive markers in platinum-resistant (PLD treated) ovarian cancer patients.https://www.mdpi.com/2075-4418/10/8/525ovarian cancertumor microenvironmentE-cadherinvimentinosteopontinosteopontin-c |
| spellingShingle | Isabel J. Dionísio de Sousa Durval S. Marques Catarina Príncipe Raquel V. Portugal Sule Canberk Hugo Prazeres José M. Lopes Etel R. P. Gimba Raquel T. Lima Paula Soares Predictive Biomarkers and Patient Outcome in Platinum-Resistant (PLD-Treated) Ovarian Cancer Diagnostics ovarian cancer tumor microenvironment E-cadherin vimentin osteopontin osteopontin-c |
| title | Predictive Biomarkers and Patient Outcome in Platinum-Resistant (PLD-Treated) Ovarian Cancer |
| title_full | Predictive Biomarkers and Patient Outcome in Platinum-Resistant (PLD-Treated) Ovarian Cancer |
| title_fullStr | Predictive Biomarkers and Patient Outcome in Platinum-Resistant (PLD-Treated) Ovarian Cancer |
| title_full_unstemmed | Predictive Biomarkers and Patient Outcome in Platinum-Resistant (PLD-Treated) Ovarian Cancer |
| title_short | Predictive Biomarkers and Patient Outcome in Platinum-Resistant (PLD-Treated) Ovarian Cancer |
| title_sort | predictive biomarkers and patient outcome in platinum resistant pld treated ovarian cancer |
| topic | ovarian cancer tumor microenvironment E-cadherin vimentin osteopontin osteopontin-c |
| url | https://www.mdpi.com/2075-4418/10/8/525 |
| work_keys_str_mv | AT isabeljdionisiodesousa predictivebiomarkersandpatientoutcomeinplatinumresistantpldtreatedovariancancer AT durvalsmarques predictivebiomarkersandpatientoutcomeinplatinumresistantpldtreatedovariancancer AT catarinaprincipe predictivebiomarkersandpatientoutcomeinplatinumresistantpldtreatedovariancancer AT raquelvportugal predictivebiomarkersandpatientoutcomeinplatinumresistantpldtreatedovariancancer AT sulecanberk predictivebiomarkersandpatientoutcomeinplatinumresistantpldtreatedovariancancer AT hugoprazeres predictivebiomarkersandpatientoutcomeinplatinumresistantpldtreatedovariancancer AT josemlopes predictivebiomarkersandpatientoutcomeinplatinumresistantpldtreatedovariancancer AT etelrpgimba predictivebiomarkersandpatientoutcomeinplatinumresistantpldtreatedovariancancer AT raqueltlima predictivebiomarkersandpatientoutcomeinplatinumresistantpldtreatedovariancancer AT paulasoares predictivebiomarkersandpatientoutcomeinplatinumresistantpldtreatedovariancancer |